LATITUDE: A Phase III, Double-Blind, Randomized Trial of Androgen Deprivation Therapy with Abiraterone Acetate Plus Predni- sone or Placebos in Newly Diagnosed High-Risk Metastatic Hormone-Naive Prostate Cancer

نویسنده

  • Keyan Salari
چکیده

Dr. Fizazi and colleagues presented their much anticipated results from the LATITUDE trial at the 2017 American Society of Clinical Oncology (ASCO) annual meeting. LATITUDE is a phase III, double-blind, randomized study that tested androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) vs. ADT + placebo in men newly diagnosed with highrisk metastatic hormone-naïve prostate cancer.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Re: Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

BACKGROUND Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of abiraterone acetate plus prednisone with androgen-deprivation therapy in patients with newly diagnosed, metastatic, castration-sensitive prostate cancer. METHODS In this double-blind, placebo-co...

متن کامل

Re: Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

PURPOSE Cure rates for localized high-risk prostate cancers (PCa) and some intermediate-risk PCa are frequently suboptimal with local therapy. Outcomes are improved by concomitant androgen-deprivation therapy (ADT) with radiation therapy, but not by concomitant ADT with surgery. Luteinizing hormone-releasing hormone agonist (LHRHa; leuprolide acetate) does not reduce serum androgens as effectiv...

متن کامل

Abiraterone: moving up in line?

Correspondence to Dr Michiel Strijbos PhD, Department of Medical Oncology, AZ Klina, Brasschaat, Antwerp 2630, Belgium; michiel. strijbos@ klina. be The crucial role of testosterone in the growth and dissemination of prostate cancer has been well known for over six decades. In his 1966 Nobel Lecture, Charles Huggins described how in his clinical studies, he discovered that endocrine manipulatio...

متن کامل

Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions

While androgen-deprivation therapy can induce dramatic clinical responses in advanced and metastatic prostate cancer, refractory disease (castration-resistant prostate cancer [CRPC]) eventually emerges. In recent years, several studies have demonstrated the importance of residual intratumoral androgens in maintaining androgen receptor (AR) transcriptional activity in CRPC. The cytochrome P450 e...

متن کامل

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility

Abiraterone acetate 1000 mg/day, combined with prednisone 5 mg PO twice daily, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate is the oral prodrug of abiraterone, a specific CYP17 inhibitor that blocks androgen biosynthesis within the adrenal glands, testes and tumor microenvironment. In a phase III trial of men with asymptomatic or...

متن کامل

ذخیره در منابع من

ذخیره در منابع من قبلا به منابع من ذحیره شده

{@ msg_add @}


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2017